Abstract:Background The efficient closure of patent foramen ovale (PFO) with short canal length and large width, usually associated with atrial septal aneurysm (ASA), remains challenging. These cases frequently require the use of larger PFO devices to avoid the risk of device embolism at the cost of a higher rate of residual shunting, mostly due to interdisk spacing. The use of atrial septal defect (ASD) prosthesis could be useful in these patients. Purpose To describe feasibility and early outcomes of the use of ASD device for percutaneous closure of widely open PFO representing an "ASD-like anatomy". Methods Since January 2022 in a high volume French university center, we started to use ASD device for percutaneous closure of selected cases of PFO with complex anatomy as mainly defined by a sheathed width of PFO ≥ 5 mm and sheathed canal length ≤ 10 mm (Figure 1) facing major per-operative residual shunt with PFO prostheses in some patients. In addition to the descriptive results, we compared this ASD device subgroup with a cohort of patients with similar anatomy but previously treated in our center with PFO device. All available transesophageal echocardiography (TEE) examinations were reviewed. The main objective was to describe the feasibility of the procedure (success and safety), the secondary endpoint was immediate post-procedural moderate to severe residual right-to-left shunt (RLS), defined as ≥ 10 bubbles in the left atrium within 3 cardiac cycles after transfemoral agitated saline injection. Results A total of 65 patients was treated with ASD devices, procedural success was achieved in all patients with a low rate (4,2%) of intrahospital complications (two supraventricular arrythmia, one anaphylactic shock and one minor laryngeal injury) and without device embolism. As compared with a cohort of 127 patients of similar anatomy treated with PFO device, patients in the ASD device group had more complex characteristics especially higher mean sheathed PFO width and shorter mean sheathed PFO canal length. Immediate post-procedural residual moderate to severe RLS did not differ significatively between groups (Table 1). No or minimal shunting was observed in 91% and 92% of cases (p=NS) but the three patients with severe RLS were all in the PFO device group. Conclusion Percutaneous closure of "ASD-like" PFO with ASD prostheses is feasible and safe. Larger studies and longer follow-ups are now required to confirm the expected improved sealing effect with this strategy.

Percutaneous patent foramen ovale closure for hypoxaemia at the age of 73: a case report showing immediate benefit

Transcatheter closure of patent foramen ovale with radiofrequency: Acute and intermediate term results in 144 patients

Platypnea-Orthodeoxia Syndrome in A Patient with A Pre-Existing Patent Foramen Ovale Successfully Treated with an Atrial Septal Occluder

Is It Worth It? A Large, Single-Center Retrospective Analysis

Patent Foramen Ovale Closure for Nonstroke Indications

Multidisciplinary Assessment Of Pfo With Substantial Right-To-Left Shunting And Medium-Term Follow-Up After Pfo Device Closure: A Single-Center Experience

Insights from a 23-Year Monocentric Analysis

An extreme case of platypnoea-orthodeoxia syndrome

Platypnea-Orthodeoxia Syndrome: Presentation of a 90-Year-Old

Partial PFO Closure for Persistent Hypoxemia in a Patient with Ebstein Anomaly

Abstract TP249: A Real World Study of PFO Closure in Young Patients With Ischemic Stroke

Feasibility and early outcomes of atrial septal defect prostheses use for percutaneous closure of widely open patent foramen ovale

Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events

Registry of Percutaneous Closure of Patent Foramen Ovale in the Secondary Prevention of Stroke

Determinants of adverse outcomes following patent foramen ovale closure in elderly patients

Device-less patent foramen ovale closure by radiofrequency thermal energy

Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?

Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke

Every Patent Foramen Ovale Should Be Closed

Case report: Anxiety and depression as initial symptoms in a patient with acute hypoxia and patent foramen ovale

Approval, Evidence, and "Off-Label" Device Utilization: The Patent Foramen Ovale Closure Story